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Abstract
Introduction: Inherited protein C (PC) deficiency is a well-known risk factor for venous thrombosis (VT).
Plasma PC levels are reliable in moderate to severe deficiencies; however, in mildly deficient individuals,
the levels may overlap with those considered normal. Genetic studies of PROC, which encodes PC, could
help identify carriers; genome-wide association studies (GWAS) have shown that approximately 50% of
phenotypic variation in PC deficiency is caused by the cumulative effects of mutations in several other
loci, namely in the PROCR. Patients and methods: With the main objective of determining the genotype/
phenotype correlation in 59 Portuguese individuals from 26 unrelated families with history of thrombosis
and repeatedly low/borderline PC plasma levels, we conducted a molecular study by direct sequencing of
PROC; PROC promoter haplotypes and PROCR c.4600A>G polymorphism (rs867186), which are known to
influence plasma PC concentrations, were also screened. Results: Twelve different PROC mutations were
identified, one of them not previously reported, p.Cys105Arg. The mutation types and locations as well as
haplotype combinations correlated with the phenotypic severity. The most frequent mutation, p.Arg199X,
correlated with the CGTC haplotype and was identified in nine families containing patients with higher
numbers of VT episodes. This mutation in homozygous individuals for the CGTC haplotype is a significant
risk factor for VT in Portuguese. Conclusion: These genetic family studies allowed the identification of the
unknown carriers and individuals at a higher thrombotic risk within each family, thus permitting the
evaluation of the need for prophylactic measures, particularly in at-risk situations.
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Protein C (PC) is a serine–protease that belongs to the vita-
min K-dependent plasma glycoprotein and zymogen group,
which plays a major regulatory role in blood coagulation
and thrombosis. PC is activated by the thrombin/thrombo-
modulin complex on the surface of endothelial cells, where
it binds with an endothelial PC receptor (EPCR) and proteo-
lytically inactivates factors Va (FVa) and FVIIIa in the pres-
ence of protein S, phospholipids, and calcium (1).
Numerous mutations in the gene coding for PC (PROC) on
chromosome 2q14 lead to several types of PC deﬁciency
(OMIM #176860) (2): in type I, deﬁciency levels of
both antigen and activity are reduced, whereas in type II,
deﬁciency antigen levels are normal, but one or more func-
tional defects lead to a decreased activity (3). Hereditary PC
deﬁciency is mainly an autosomal dominant inherited disor-
der, is an established risk factor for venous thrombosis (VT)
(4) and arterial ischemic stroke in children (5), and has been
associated to arterial thrombosis events at a young age (6).
The relative risk increases as the PC concentration falls, with
an odds ratio (OR) of 4 in individuals with PC levels of
<65% (7). PC deﬁciency appears to be quite rare, with a
prevalence of 0.14–0.50% in the general population and
2.5–6% in patients with venous thrombosis. Heterozygous
individuals have an approximately sevenfold increased risk
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of VT compared with normal individuals (8). The rare form
of PC deﬁciency, severe homozygous (or compound hetero-
zygous), was ﬁrst described as a cause of neonatal purpura
fulminans resulting in rapid death caused by massive venous
thrombosis (9, 10). However, a number of adult patients
with very low or undetectable plasma PC levels have been
found; they exhibit milder symptoms and/or a later onset of
the disease (11).
The diagnosis of PC deﬁciency based on plasma measure-
ments is often difﬁcult in patients with borderline plasma PC
levels, due to the fact that not all heterozygotes for a given
mutation have a low plasma PC level and because of the
large overlap between heterozygotes and non-carriers (3, 7,
12, 13). It should also be noted that the decrease in plasma
PC concentrations is inﬂuenced by age, where the PC con-
centration level may remain below the adult reference range
until adolescence (14, 15).
Genetic studies offer a powerful complementary tool,
although the alterations found in PROC are due to either
rare mutations or common single nucleotide polymorphisms
(SNPs). However, in about 10–30% of families with PC
deﬁciency, the mutations are not detectable (16).
The SNPs within the 50 region of PROC, which causally
contribute to down transcriptional regulation, show a correla-
tion with low plasma levels of PC and are associated with
adverse outcomes in a variety of clinical states. These SNPs,
which extend from the promoter region to the end of
intron 2, 1657C/T (rs1799808); 1644A/G (rs1799809);
1479A/T (rs1799810); and 141T/C (rs1158867), show a
high degree of linkage disequilibrium (LD) (7, 12, 17). The
CGT haplotype of 1657C/T, 1644 A/G, and 1479A/T is
generally related to lower plasma PC levels than the comple-
mentary TAA haplotype and to a higher risk of thrombotic
events. The transcriptional efﬁciency of PROC in these haplo-
types has been described as driven by the SNPs at positions
1657 and 1644. The other two SNPs, 1479A/T and
141T/C, are in complete LD (r2 = 1) and may be involved in
regulating splicing events with moderate thrombotic risk (17).
The search for additional polymorphisms, through the gen-
ome-wide association studies (GWAS), has been conducted
for loci affecting plasma PC levels, and it has been found
that 50% of the phenotypic variation is caused by the addi-
tive effect of SNPs in other genes (18, 19). With this in
mind, many studies have been carried out, but only SNPs in
the EPCR gene (PROCR) located on chromosome 20q11.2
have been robustly found to be associated with the risk of
VT in diverse GWAS (18, 20, 21). The PROCR polymor-
phism that shows the highest association with PC levels is
the c.4600A>G (rs867186), causing a serine to glycine sub-
stitution at amino acid 219 (p.S219G), located in the trans-
membrane domain of the EPCR protein. This functional
variant showed increased soluble EPCR plasma levels,
which explains the increase of PC levels in plasma and con-
tributes to about 10% of their variability (22, 23).
PC deﬁciency can also be found in association with other
genetic defects predisposing for VT including the factor V
Leiden (F5L) and prothrombin G20210A gene polymor-
phisms. It has been shown that individuals with both PC
deﬁciency and F5L have a higher risk of developing throm-
bosis at a younger age as compared with carriers of PC deﬁ-
ciency alone (24, 25). In individuals with PC deﬁciency,
environmental factors (e.g., pregnancy, puerperium, oral
contraceptives, surgery, immobilization, and trauma) are
cumulative high-risk factors for thrombosis.
To determine the genotype/phenotype correlation of 59 Por-
tuguese individuals, from 26 unrelated families with a history
of personal and/or familial thrombosis, who had repeated low
or borderline PC plasma levels, we carried out the molecular
study and the haplotype analysis for those polymorphisms
which are known to inﬂuence the plasma PC concentration.
Patients and methods
This study includes a group of 59 patients of Portuguese origin
belonging to 26 apparently unrelated families, diagnosed with
PC deﬁciency between 2002 and 2012, attending the Department
of Haematology at the Centro Hospitalar de Coimbra, Portugal.
Clinical description of the probands and their families
The probands were attended in our Center for thrombophilia
screening after the thrombotic event or because of their family
history of thrombosis. The clinical characteristics of patients
were recorded, through a validated questionnaire, focusing on
personal and family history of thrombosis disease and
acquired risk. Among the 26 probands, 22 had a personal his-
tory of thrombosis: two had had arterial thrombosis; two
obstetrical complications; 13 venous thromboembolism (11
lower limbs deep vein thrombosis, one lower limbs deep vein
thrombosis with pulmonary embolism and one portal vein
thrombosis) and ﬁve superﬁcial vein thrombosis. The remain-
ing four probands were asymptomatic and studied because
ﬁrst- and second-degree relatives had had venous thrombosis
(The detailed list of clinical data can be found in Table 1).
The mean age of the probands at diagnosis was
39.27  17.25 yrs with a sex distribution 17F : 9M; the
mean age at the time of the ﬁrst thrombotic episode was
24.67  16.94 yrs; 11 (42%) had experienced more than
one thrombotic episode. Nineteen probands had acquired risk
factors: contraceptive drugs, varicose veins, trauma, preg-
nancy, dyslipidemia, hypertension, and immobilization.
Three probands aged 24.33  7.57 of whom had more than
one thrombotic episode, had no identiﬁed risk factors and
identiﬁed risk factors and were considered as having had an
idiopathic deep venous thrombosis (DVT) (Table 1). Of the
26 probands, fourteen (53.8%) had a positive family history
of VT; an examination of their relatives revealed 33 with PC
deﬁciency, but only 7 (21%) had had thrombotic episodes.
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Controls
Fifty-two healthy volunteers acted as a control group for mea-
suring of PC activity/antigen levels of adult’s normal range,
and for determining the PROC promoter haplotypes and
p.S219G genotypes in PROCR. The control group include
unrelated individuals from laboratory and medical staff
(38F : 14M), without an individual or family history of
thrombosis, with a mean age of 33.5 yrs  11.12. Absence of
thrombotic events or a family history of thrombosis was veri-
ﬁed by means of a validated questionnaire. The thrombophilia
study was also carried out in the control group subjects.
In accordance with the Helsinki Declaration, informed
consent was obtained from patients and controls.
Samples and sample processing
All samples of thrombophilia patients were taken with a
minimum of 3 months after the last episode of thrombosis
and off anticoagulant therapy for at least 30 d.
Functional and immunological studies were performed on
blood collected into vacuum tubes containing 3.2% sodium
citrate and centrifuged within 15 min at room temperature
for 20 min at 2500 g; the obtained platelet poor plasma is
then separated into aliquots and kept frozen at 80°C until
use. The separated plasma was later subjected to the func-
tional thrombophilia tests.
Genomic DNA was extracted from EDTA whole blood by
automatic isolation on iPrepTM instrument using gDNA
Blood Kit (Invitrogen, Carlsbad, CA, USA).
Thrombophilia screening
The following tests were performed in all probands and their
relatives:
1. Functional thrombophilia tests – Antithrombin activity, PC
amidolytic activity, protein S free and detection of lupus
anticoagulant run on ACL TOP (Instrumentation Laboratory,
Milan, Italy). PC antigen, protein S total were determined by
enzyme-linked immunosorbent assay (DG-EIA– Grifols,
CorgenixTM, Corgenix, Broomﬁeld, Colorado, USA).
2. Molecular thrombophilia tests – The screening of F5L
and the prothrombin 20210A allele was carried out using












PC.1 45/F SVT (35) Meniscus fracture, immobilization RT (39, 44) 0
PC.2 31/F DVT(19) No RT (20, 21) 1
PC.3 64/F SVT (44) Hypertension and diabetes PE (64) 0
PC.4 33/F 2 stillbirths 34/30 wks by placental thrombosis 0
PC.5 33/F Asymptomatic1 – 1
PC.6 24/F DVT (24) Oral contraceptive 0
PC.7 21/M SVT (21) No RT (22, 23); DVT (29) 1
PC.8 23/F DVT; PE (19) Oral contraceptive, 2 miscarriages (18, 23) 0
PC.9 28/F DVT (26) Oral contraceptive, long trip 0
PC.10 35/M DVT (33) No CTPV (33) 0
PC.11 56/M DVT (56) Varicose veins, smoker, and dyslipidemia SVT (57) 1
PC.12 26/F DVT (20) Oral contraceptive, sedentary lifestyle DVT (27) 2
PC.13 68/F DVT (34) Delivery 1
PC.14 48/M DVT (46) Surgery varicose veins, obesity, sedentary lifestyle DVT (47) 0
PC.15 33/M SVT (33) Varicose veins 1
PC.16 67/M Asymptomatic1 – 2
PC.17 13/M Asymptomatic1 – 1
PC.18 19/F DVT (17) Oral contraceptive 0
PC.19 42/F Stroke (42) Dyslipidemia 0
PC.20 45/F DVT (20) Pregnancy, varicose veins DVT, T (34) 2
PC.21 16/M Asymptomatic1 – 1
PC.22 47/M DVT (47) Renal transplant patient 0
PC.23 Neonate/F Arterial cerebral thrombosis, ischemia, and amputation of the fingers of the right hand 1
PC.24 23/F Recurrent miscarriages 0
PC.25 33/F SVT (19) Hypertension, varicose veins, obesity RT (22, 26, 33) 1
PC.26 29/F DVT (26) Delivery 1
VT, venous thrombosis; DVT, deep vein thrombosis; SVT, superficial vein thrombosis; PE, pulmonary embolism; RT, recurrent superficial vein
thrombosis; cavernous transformation of the portal vein (CTPV).
1Referred to thrombophilia screening by their family history of VT.
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modiﬁed multiplex allele-speciﬁc polymerase chain reac-
tion (PCR).
Diagnosis of PC deficiency
The PC amidolytic activity was determined using a chromo-
genic end-point assay (HemosILTM Protein C; Instrumenta-
tion Laboratory), because it is less prone to interferences
(26); although when a low ratio of activity to antigen and in
order to detect deﬁciencies type II, the PC anticoagulant
activity was also determined by a coagulation end-point
assay using ProClot assay derived from Protac (Instrumen-
tation Laboratory, Orangeburg, NY, USA) performed in
accordance with the manufacturer’s instructions.
The adult’s normal ranges were established in 52 healthy
controls (mean  2 SD): PC activity 73–143% and PC anti-
gen 71–135%. The sample values of children and adoles-
cents were compared with the published pediatrics reference
ranges with standardized age groups (14, 15).
The diagnosis of potential probands with deﬁciency of PC
was established on the basis of the following criteria: plasma
levels of PC below the lower normal range cutoff values in
at least two different samples.
PROC and PROCR genotype analysis
All exons, intronic boundaries, 50 and 30 UTRs of the PROC
gene were PCR ampliﬁed using primers as described previ-
ously (27) with the exception of the following primers used
for ampliﬁcation of: (i) PROC promoter SNPs rs1799808,
rs1799809, and rs1799810: Prm_50-CCTCCCCTGCCCGCA
GA-30; Prm_50-CGTGATTCCTGGGCGATGTATT-30; (ii)
SNP rs1158867: Int1_50-ACTGCATTCTGGAGCTGCTT;
Int1_GAAAGGGCTGTCCCTGTGT; and (iii) PROCR SNP
rs867186: SG_50- GCTCCTACACTTCGCTGGTC; SG_50-
GAGCTGAAACTTTCCCTTGC. After ampliﬁcation, the
PCR products for all samples were sequenced on an ABI
PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA) using Big Dye Terminator v1.1 Cycle
Sequencing Chemistry (Applied Biosystems), according to
protocols recommended by the manufacturer.
DNA samples from patients lacking identiﬁed mutations
using PCR/direct sequencing were screened using multiplexed
ligation-dependent probe ampliﬁcation (MLPA) method with
the Kit P265-B1 PROC (MRC, Amsterdam, the Netherlands).
New sequence variants and amino acid changes were
designated according to current nomenclature and the recom-
mendations of the Human Genome Variation Society –
Accession Number JX030036.
In silico analysis of amino acid changes
The possible impact of coding sequence changes (amino
acid substitutions) on the structure and function of PC was
assessed using three bioinformatics tools: Sorting Intolerant
From Tolerant (SIFT, http://sift.jcvi.org), Polymorphism
Phenotyping-2 (PolyPhen-2, http://genetics.bwh.harvard.edu/
pph2/), and MutationTaster (http://mutationtaster.org/).
Statistical analysis
For continuous variables, differences between groups were
analyzed by a Student’s t-test or Mann–Whitney U-test,
depending on the normality of the data. A distribution of
haplotypes between the studied groups was analyzed using
Fisher’s exact test. Tests were assumed signiﬁcant whenever
at 2-tailed P < 0.05. These statistical analyses were per-
formed using GraphPad Prism 6.02 for Windows (GraphPad
Software, La Jolla, CA, USA, www.graphpad.com).
Allele frequencies estimated by simple counting, Hardy–
Weinberg equilibrium probability values, as well as linkage
phase statistical inference from diploid data with the (Bayes-
ian) ELB algorithm and haplotype frequencies, were
obtained using the software Arlequin, version 3.01 (Excof-




Forty-three patients were determined to have plasma PC activ-
ity levels below 60%; the remaining 16 patients received oral
anticoagulation (n = 4) or had slightly decreased values (60–
73%) along with family histories that suggested PC deﬁciency
(n = 12). Therefore, 57 individuals were classiﬁed with type I
PC deﬁciency and two with type IIa deﬁciency (PC22; PC24)
with normal antigen concentrations and reductions in both
amidolytic and anticoagulant activities.
These 59 patients with suspected PC deﬁciency were sub-
jected to PROC gene analysis. Twelve different mutations
were identiﬁed, of which only one was not previously
reported in the Human Gene Mutation Database (HGMD).
The majority of these were missense (9/12; Fig. 1) and
included p.Cys105Arg (not previously described), p.Pro210-
Leu, p.Gly215Glu, p.Arg220Gln, p.Gly239Arg, p.Val339-
Met, p.Pro369Leu, p.Arg394Trp, and p.Trp444Cys, whereas
the remaining three were a nucleotide change (13A>G) at
the promoter region, a nonsense mutation (p.Arg199X), and
a small deletion (p.Leu212Hisfs*2). No mutations were
found in one family with low PC levels. Patients among the
60–73% of those with PC activity levels overlapping the
minimal values of the control group mostly belonged to the
group with type 1 missense mutations (Fig. 2).
Screening for other inherited thrombophilias revealed the
co-inheritance of heterozygous F5L in ﬁve individuals from
three families (PC13, PC18, and PC23) and heterozygosity
for a prothrombin G20210A variant in three individuals
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from two families (PC13 and PC14). One patient was
homozygous for F5L (PC23) and another was heterozygous
for F5L and prothrombin G20210A (PC13.I).
Influence of PROC and PROCR polymorphisms on
plasma PC levels
The distribution of PROC promoter haplotypes based on the
SNPs 1657C/T, 1644A/G, 1479A/T, and 141T/C as
well as the c.4600A>G and p.S219G (PROCR) genotypes
among the 52 controls and 26 probands is shown in Table 2.
Genotype distributions among the control group were in
agreement with Hardy–Weinberg equilibrium for all ﬁve
polymorphisms (P > 0.05). Although the CGTC, TAAT,
and CAAT PROC promoter haplotypes were observed in
both controls and patients, the CGTC frequency was signiﬁ-
cantly higher among patients than among controls
(P = 0.005). However, the PROCR c.4600A>G polymor-
phism allele frequencies were similar in both groups (minor
allele frequency: controls 0.106 vs. patients 0.096;
P = 0.713).
We further identiﬁed the haplotypes associated with each
PROC mutation using the four evaluated PROC promoter
SNPs (Table 3). The three different haplotypes, CAAT,
TAAT, and CGTC, were observed both in normal and muta-
tion carrier chromosomes. Mutations that occur more than
once in unrelated probands were always found in the context
of a single haplotype. From the twelve identiﬁed mutations,
the most common nonsense mutation (c.595C>T; chr = 9)
and four other missense mutations were associated with the
CGTC haplotype; four other different missense mutations
were associated with the CAAT haplotype; and the remain-
ing three different types of mutation (one missense, one pro-
moter, and a small deletion) were associated with the TAAT
haplotype (Table 3).
The respective inﬂuences of the three haplotypes
(CGTC, TAAT, and CAAT) and the c.4600A>G genotypes
on plasma PC activity were then analyzed in the controls
and patients (Fig. 3A). In the control group, the mean PC
activity values in the CG haplotype carrier groups exhib-
ited a downward trend from CGTC/CAAT = 108.7% (95%
CI, 93.62–123.8) to CGTC/TAAT = 106% (95% CI,
95.44–116.6) and ﬁnally, CGTC/CGTC = 100% (95% CI,
88.5–111.5). In contrast, the PC activity values varied
while exhibiting an upward trend from CAAT/CAAT =
103.2% (95% CI, 74.93–131.15) to TAAT/CAAT =
112.9% (95% CI, 97.74–128) and ﬁnally, TAAT/
TAAT = 115.6% (95% CI, 104.7–126.5; Fig. 3A). This
downward to upward tendency was supported by the sig-
niﬁcantly different PC activity values between CGTC/
CGTC and TAAT/TAAT carriers (P = 0.0362). The mean
PC activity values observed in controls regarding the
PROCR c.4600A>G genotypes differed signiﬁcantly
(P = 0.0087), with rates of 119.6% (95% CI, 109.7–
129.6), with the c.4600AG genotype vs. 104.4% (95% CI,
99.08–109.7), and with the c.4600AA genotype (Fig. 3B).
In the patient group, the three PROC haplotypes and
PROCR c.4600A>G genotypes did not induce signiﬁcant




Figure 1 Twelve different mutations were identified in 25 families: promotor 13A>G; nonsense p.Arg199X; small deletion p.Leu212His-
fs*2, and missense p.Cys105Arg (not previously described), p.Pro210Leu, p.Gly215Glu, p.Arg220Gln, p.Gly239Arg, p.Val339Met, p.Pro369Leu,
p.Arg394Trp, and p.Trp444Cys. The scheme represents their location through of PROC gene (A) and correspondence of functional or structural
domains of protein (B).
Figure 2 Box–Whisker and dot plots of protein C (PC) activity levels
vs. type of mutations. PC activity levels according to the different
types of mutation, with each dot representing a single case. The gray
zone limits the levels of PC activity 60–73%.
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Genetic background of protein C deficiency
The inﬂuence of polymorphisms on plasma PC levels was
analyzed in detail on each of the 26 families, as well as pot-
entiates the phenotype of 12 different mutations. The geno-
type/phenotype correlation was assessed for each of the
mutations, their positions, PC activities, and antigen concen-
trations (Table 4). Only one patient exhibited mutational
homozygosity (p.Arg220Gln); all others were heterozygous.
The four individuals aged ≤17 yrs (one neonate, one aged
7 yrs, and two prepubertal patients aged 13 and 16 yrs) who
carried different mutations exhibited signiﬁcantly lower PC
activity levels as compared with older relatives carrying the
same mutations (Mann–Whitney U-test, P = 0.010). The
individuals aged ≤17 yrs and the homozygous subject were
analyzed and reported separately because of these differ-
ences in activity levels (Table 4).
Promoter mutation: The 13A>G mutation (La Jolla IV)
was shown to abolish 1 of 2 putative HNF-3 binding sites
affecting PC promoter transactivation (28). This TAAT hap-
lotype-associated mutation correlated with type I deﬁciency
in eight individuals from four families (Table 4); members
Table 2 Distribution of the promoter haplotypes (PROC) and




n (%) n (%)
Haplotype combinations1
CGTC/CGTC 9 (17.3) 8 (30.8)
CGTC/TAAT 15 (28.8) 8 (30.8)
CGTC/CAAT 7 (13.5) 2 (7.7)
TAAT/TAAT 8 (15.4) 3 (11.5)
TAAT/CAAT 8 (15.4) 3 (11.5)
CAAT/CAAT 5 (9.6) 2 (7.7)








AA 41 (78.9) 21 (80.8)
AG 11 (21.1) 5 (19.2)





1SNP sequence as follows: 1657C/T, 1644A/G, 1479A/T, and
141T/C.
**Chi-square test (O,E) – 2-tailed, df = 2, for CGTC haplotype
between controls and probands.
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of two of these families were also heterozygous for PROCR
c.4600 A>G polymorphism. The highest PC activity (70–
65%) and antigen (69–61%) levels belonged to two relatives
who carried the CAAT haplotype in trans and heterozygous
for the c.4600 A>G polymorphism, one of whom was also a
F5L carrier. Two probands (PC.1 and PC.18) experienced
VT episodes associated with acquired risk factors (immobili-
zation due to a fractured meniscus and oral contraceptive
use), with ages of onset of 35 and 17 yrs, respectively. The
latter also carried the CGTC haplotype in trans and the
c.4600 AG genotype.
Nonsense mutation: The c.595C>T (p.Arg199X) mutation
in exon 7 is on a hypermutable CpG site and introduces a
premature termination codon in the connecting dipeptide
(Lys198–Arg199) of the light and heavy chains, thus caus-
ing disturbances in thrombin-mediated PC activation (29).
This mutation, which is associated with type I PC deﬁ-
ciency, was identiﬁed in a heterozygous state in nine pro-
bands and nine relatives and was thus the most prevalent
mutation among the patients (36%). All 18 patients carried
the PROC promoter CGTC haplotype: nine homozygotes
and nine heterozygotes. Among these, 11 of 18 patients
(61%) exhibited early VT complications (age range, 19–
44 yrs), and in one case, pulmonary embolism was also
diagnosed (Table 1). Eight of the nine individuals homozy-
gous for CGTC had thrombosis. One proband (PC.13) and
his two relatives also had F5L, with one relative additionally
carrying the prothrombin G20210A variant although this
individual was asymptomatic. Of these three individuals,
only the proband was homozygous for the CGTC haplotype.
It is also noteworthy that the only three patients from this
group (two probands and one relative) who had idiopathic
DVT were homozygous for the CGTC haplotype; one of
them also carried the c.4600 AG genotype. The fact that the
18 p.Arg199X mutation carrier chromosomes are in com-
plete linkage disequilibrium with a unique CGTC haplotype
suggests that at least within the Portuguese population, the
c.595C>T nucleotide change occurred once on this progeni-
tor haplotype.
Small deletion: The c.633_634 del GC (Leu212Hisfs*2)
mutation is located in the activation cleavage site at Arg211?
Leu212, where thrombin cleavage releases a dodecapeptide
from the heavy chain; this mutation thus interferes with an
indispensable role of the PC structure (1). This mutation was
identiﬁed in two families (three individuals) with type I PC
deﬁciency and existed with the TAAT haplotype (Tables 3
and 4). Only one individual who was also heterozygous for
CGTC haplotype (in trans) developed idiopathic DVT; the
other two were asymptomatic (one adult and one child) and
presented TAAT haplotype heterozygosity and homozygosity,
respectively, thus suggesting a protective effect of this haplo-
type. None of these individuals carried the PROCR c.4600AG
genotype. Besides this study, this deletion has been reported
once by another Portuguese group, suggesting that it may have
a common ancient origin (30).
Missense mutations: Seven were associated with type I PC
deﬁciency: one in the EGF1 domain, p.Cys105Arg, one in
the activation peptide p.Pro210Leu, and ﬁve in the serine–
protease domain, speciﬁcally p.Arg220Gln, p.Gly239Arg,
p.Val339Met, p.Pro369Leu, and p.Trp444Cys. The two
mutations associated with type II deﬁciency both occurred in
the serine–protease domain: p.Gly215Glu and p.Arg394Trp.
The bioinformatics analyses of these mutations revealed that
eight were classiﬁed as ‘Probably damaging’ and one as
‘Benign’ by PolyPhen, whereas seven were classiﬁed as
‘Damaging’ and two as ‘Tolerated’ according to SIFT; addi-
tionally, the Mutation Taster prediction was ‘Disease causing’
for seven and ‘polymorphism’ for two (Table 4). All missense
mutations occurred in amino acids that were conserved across
species except for p.Arg220Gln and p.Pro369Leu.
A
B
Figure 3 Box–Whisker and dot plots of protein C (PC) activity levels
within PROC promoter haplotype combinations (A) and PROCR c.
4600 A>G (p.S219G) genotypes (B). (A) PC activity of controls and
patients is sorted by six haplotypes combinations and compared to
CGTC/CGTC by t-test. (B) PC activity of controls and patients is sorted
by c. 4600 AA and AG genotypes and compared by t-test. The gray
zone limits the levels of PC activity 60–73%. Significance level was
0.05. If not indicated otherwise comparison was statistically non-sig-
nificant. (C), controls; (P) patient.
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The three deleterious mutations in the catalytic region,
p.Gly239Arg, p.Val339Met, and p.Trp444Cys, occurred in
four families with type I deﬁciency and were predicted by
PolyPhen, SIFT, and Mutation Taster as ‘damaging’, ‘very
high risk’, and ‘Disease mutation’. These three PC amino
acids are highly conserved across orthologs and are thus
structurally important. Speciﬁcally, in Trp444, the replace-
ment of large tryptophan aromatic ring with a small cysteine
hydrophilic side chain leads to tertiary structure destabiliza-
tion (31). On the other hand, the p.Pro369Leu substitution
affects a non-conserved amino acid.
The new mutation p.Cys105Arg was associated with a
type I deﬁciency in one family (three members). The three
individuals carried the same promoter PROC haplotype com-
bination of CAAT/TAAT and PROCR genotype c.4600AA;
however, only the proband developed thrombosis associated
with an acquired risk factor (dyslipidemia). This variant was
absent in all 50 healthy individuals, suggesting that it is not
a common polymorphism.
The p.Pro210Leu mutation that includes the PROC haplo-
type combination (CGTC/CAAT) and PROCR genotype
c.4600AA was associated with type I deﬁciency in one fam-
ily (four members). The proband with a previous risk factor
(oral contraceptive use) developed a DVT during a long car
trip.
Another mutation found in the proximity of the thrombin
activation site was p.Gly215Glu, which was detected with a
type II variant as mentioned in the database HGMD (protein
C pecs 3) (29). This mutation was found in a renal trans-
plant patient who had been asymptomatic until age 47 yrs,
the time at which the patient had developed a DVT as a
result of an arteriovenous prosthetic device (PC.12). The
patient’s haplotype combination was CAAT/TAAT and
PROCR genotype c.4600AA.
The missense mutation, identiﬁed in family PC.14,
p.Arg220Gln, was reported as the most recurrent in the data-
base HGMD (32). This locus exhibits three different amino
acid substitutions (Gln, Gly, and Pro), with the Gln substitu-
tion predicted by both PolyPhen and SIFT as the most
‘benign’ and ‘tolerated’, respectively. Four members of fam-
ily PC.14 were heterozygous and one member was homozy-
gous for this substitution, which caused a PC type I
deﬁciency phenotype. Only two heterozygous subjects had
suffered thrombotic events and the homozygous subject,
despite having much lower PC levels, remained asymptom-
atic at 22 yrs of age. However, this family member is quite
young and the possibility that she developed thrombosis can-
not be ruled out upon exposure to risk factors such as
trauma, infection, and pregnancy. The proband, who was
heterozygous for the prothrombin G20210A variant, suffered
a DVT after surgery for varicose veins. The promoter PROC
haplotypes were CAAT/CAAT (n = 3), CAAT/TAAT
(n = 1), and CAAT/CGTC (n = 1), and all ﬁve individuals
carried PROCR c.4600AA genotype.
The mutation p.Gly239Arg in the serine–protease domain
(33) was reported in a 60-yr-old man who remained asymp-
tomatic until age 56 yrs (PC.11), the time at which DVT
occurred in the presence of the acquired risks of varicose
veins, smoking, and dyslipidemia. The promoter PROC hap-
lotype was homozygous CAAT/CAAT with the PROCR
genotype c.4600AA. The effect of this deleterious mutation
may have been attenuated by the polymorphism genotypes,
and DVT may have been triggered by the acquired risks.
The mutation p.Val339Met was present in two families
(four individuals). Among all missense mutations, this was
associated with the lowest PC values and the two probands
had developed DVT at earlier ages (24 and 26 yrs), thus
conﬁrming the deleterious nature of this mutation as
described by other authors (34). Besides the contributions of
acquired risk factors (oral contraceptive use and delivery) to
DVT development, the promoter PROC haplotype CGTC
was present in homozygosity (n = 1) and in combination
with TAAT (n = 3) and the PROCR genotype c.4600AA.
The p.Pro369Leu substitution has been associated with a
mild phenotype (2). However, this substitution was found in
a woman with early-onset VT (20 yrs of age) associated
with pregnancy and varicose veins; this patient’s promoter
PROC haplotype combination was CGTC/TAAT with the
PROCR genotype c.4600AG. In this case, CGTC in cis and
the c.4600AG genotype may have contributed to the cumu-
lative thrombotic effect of this mutation.
The p.Arg394Trp substitution occurs in the immediate
vicinity of the active site S402 (2) and has been associated
with a type II deﬁciency state that was detected in proband
PC.14. The carrier of this mutation was a young woman
(age, 24 yrs) who had experienced recurrent ﬁrst-quarter
miscarriages; the promoter PROC haplotype was homozy-
gous for CGTC and PROCR genotype c.4600AA. Co-inheri-
tance of the homozygous CGTC haplotype may have had a
cumulative effect and contributed to the increased pheno-
typic severity.
The proband of the family carrying the p.Trp444Cys
mutation (31) was an infant who suffered an episode of
severe neonatal thrombosis. An arterial cerebral thrombosis
during the infant’s ﬁrst day of life followed by subsequent
venipuncture for phenobarbital administration led to ische-
mia requiring amputation to the proximal interphalangeal
joints of the second, third, and fourth ﬁngers of the right
hand. This family (three individuals) exhibited F5L co-inher-
itance; the infant and her mother were found to be homozy-
gous and heterozygous, respectively. The mother developed
thrombophlebitis during puerperium and the infant’s sister
remained asymptomatic until 20 yrs of age. It is known that
the inheritance of F5L and PROC gene lesions is associated
with a cumulative thrombotic risk (10). In this case, the
inheritance of a single allele with PROC mutation along
with the two F5L alleles was a potentially critical precipitat-
ing event in the early-onset thrombotic episodes in the
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 303
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affected infant. Curiously, the promoter PROC haplotype
was present in both the protective homozygous TAAT/
TAAT (proband and her sister) and heterozygous TAAT/
CGTC (mother) forms; all three individuals carried the
PROCR genotype c.4600AA. We may therefore speculate
that in the infant’s sister, the effect of the Cys444-mutated
allele on the PC levels may have been attenuated by the
presence of the TAAT haplotype and was thus higher than
expected. Regarding the proband child, this haplotype com-
bination (TAAT/TAAT) may have had a positive modula-
tory effect on the Cys444 mutation and co-inherited
homozygous F5L.
Remaining unidentiﬁed molecular lesions: Although the
PC activity levels of proband PC.12 were low and phenotyp-
ically consistent with type I PC deﬁciency (activity, 14%;
antigen, 17%), no molecular alterations in PROC were iden-
tiﬁed in this family (seven individuals) via promoter, exon,
and splice-ﬂanking region sequencing. Three of seven indi-
viduals experienced VT episodes. The promoter PROC hap-
lotype CGTC was present in both the heterozygous states
CGTC/CAAT (n = 3) and CGTC/TAAT (CGTA, n = 3)
and the homozygous state (n = 1) along with the PROCR
genotype c.4600AG. The MLPA analysis screening, which
is crucial for identifying regions with large molecular
defects, did not reveal any alterations. In this case, mutations
may have occurred in intronic regions or locus-controlling
regions within PROC or in regions outside of the gene that
are important for its expression. mRNA studies may help to
elucidate the underlying mechanism.
Genotype/Phenotype analysis
Assuming that the PC activity correlated inversely with the
risk of thrombosis and that genetic risk factors have a cumu-
lative effect, the proportion of thrombotic episodes in the
patients was analyzed according to the 12 different muta-
tions and respective haplotypes. The patients were separated
according to the occurrence or not of thrombotic episodes to
determine the background genetic differences (Fig. 4). It
should be noted that patients with PC activity levels ranging
from 60% to 73% were mostly included in the group with-
out thrombosis. Conversely, in the group of patients with
thrombosis, nearly all had PC levels below 60% and the
majority was homozygous for the CGTC haplotype. When
the thrombotic events were compared relative to haplotypes
(Fig. 5A), patients homozygous for the CGTC haplotype
were found to have experienced a signiﬁcantly higher num-
ber of thrombotic events than were other patients
(P = 0.0048), with a relative risk of 2.3 (95% CI = 1.5–
3.6). As shown in Fig. 5B, the greater proportion of patients
homozygous for CGTG (82%) carried the common nonsense
mutation c.595C>T (p.Arg199X), and this association con-
ferred a relative thrombosis development risk of 2.1 (95%
CI = 1.3–3.2).
Discussion
Thrombosis is a complex disease in which each individual’s
susceptibility to the disease is determined by the effects of
both genetic and acquired risk factors (23, 26). PC deﬁ-
ciency is an established risk factor for thrombosis; however,
diagnosis based on laboratory plasma level cutoffs is often
difﬁcult, and therefore, establishing patients’ disease severity
and risk of thrombosis becomes challenging. However, fam-
ily studies are crucial because as proven by several studies,
and genetic factors make an approximate 60% contribution
to VT (35).
This study comprised a genotype/phenotype correlation in
26 unrelated families with suspected inherited PC deﬁciency.
Twelve different PROC gene mutations were identiﬁed in 25
A B
Figure 4 Protein C (PC) activity levels in different mutations and promoter PROC haplotype combinations–distribution by group of patients with
thrombosis vs. group of patients without thrombosis. Patients with PC activity levels between 60% and 73% (gray zone) were mostly included in
the group without thrombosis; conversely in the group of patients with thrombosis nearly all had PC levels below 60% and the majority was
homozygotes for CGTC haplotype.
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of the 26 families (96%). The genotype/phenotype correla-
tion was analyzed while considering some known modulat-
ing factors such as age, acquired factors, and polymorphisms
in the PROC and PROCR genes.
Variability in the plasma PC levels according to age was
marked in these families with PC deﬁciency, which supports
the use of age-related normal reference intervals (15). The
lowest PC levels observed in individuals <17 yrs (two chil-
dren and two prepubertal individuals) could be explained by
a genetic mechanism that underlies the age-related regulation
of PROC gene expression. This mechanism acts as a pub-
erty-onset gene switch with an age-related stability element
(ASE) that stabilizes gene expression at the pre-puberty,
which is then followed by an age-related increase in gene
expression (36).
A correlation between PROC promoter haplotypes and the
PROCR c.4600AG polymorphism with respect to plasma PC
levels was noted in the 52 controls. The mean PC activity
level in individuals homozygous for the PROC CGTC hap-
lotype was approximately 15.6% less than that of individuals
homozygous for the TAAT haplotype. Regarding PROCR
c.4600AG, the mean PC activity level in individuals carry-
ing the c.4600G allele was 15% higher. These results from
the control group conﬁrm that the PC levels in healthy indi-
viduals are determined by genetic variations. As mentioned
in other studies (7, 12, 16, 17, 24), the higher CGTC haplo-
type frequency in the patients in the present study
(P = 0.005) demonstrated the inﬂuence on the thrombotic
risk. This association was proven by the higher number of
thrombotic episodes experienced by patients homozygous for
the CGTC haplotype; conversely, patients homozygous for
the TAAT haplotype had the lowest incidence of such
events, supporting the notion of a protective effect as sug-
gested previously by other authors (7).
Each of the 12 background genetic mutations justiﬁes the
worsening or improvement of a different phenotype (throm-
botic risk). These differences are associated with the combi-
nations of mutation types as well as the co-inherited PROC
promoter haplotype. Therefore, it was possible to observe a
positive modulatory effect on the 13A>G and p.
Leu212Hisfs*2 mutations conferred by the TAAT haplotype
(Fig. 4, Table 4). Similarly, the homozygous patient for
Arg220Gln mutation showed relevant PC levels (19–20%),
what could be explained by a cumulative effect of the
benign characteristic of this missense mutation (PolyPhen-2
prediction score = 0.357) associated with the haplotype
CAAT/CAAT. In contrast, individuals with mutations that
co-inherited the CGTC haplotype such as p.Arg199X and
four missense mutations (p.Pro210Leu, p.Val339Met,
p.Pro369Leu, and p.Arg394Trp) suffered from a negative
modulatory effect. The most frequent p.Arg199X mutation
was identiﬁed in nine families that contained patients with
higher numbers of VT episodes. Regarding missense muta-
tions, we can speculate that the inﬂuence of the CGTC hap-
lotype is reﬂected in the associated earlier mean age of onset
relative to that in patients with other mutations (Table 4).
In this small study, the authors did not set out to make
new discoveries related to etiological and PC deﬁciency
mechanisms. Large studies with that intent have already
been performed and have provided new insights into throm-
bosis development (37). However, it is necessary to apply
these insights into the context of familial studies to deter-
mine their usefulness for individual risk prediction (38). We
have integrated some of this recent knowledge about the
inﬂuence of SNPs on plasma PC levels in families with
thrombotic events. We performed a genotype/phenotype cor-
relation and noted the thrombotic event severity (type and
number) with respect to the background genetic factors and
acquired risk factors present in each family. More speciﬁ-
cally, the correlation of the mutation type and location as
well as the PROC CGTC haplotype and PROCR c.4600AG
genotypes with the severity of the phenotype could be veri-
ﬁed. For each family, it was possible to establish the genetic
background and assess the thrombotic risk associated with
each element. The common mutation p.Arg199X correlates
with the PROC CGTC haplotype and an increased risk of
VT in the Portuguese population. The SNP c.4600A>G in
PROCR may explain differences in the PC plasma levels in
individuals with the same mutation. These facts support the
hypothesis that next-generation sequencing (NGS) studies
will allow the identiﬁcation of other risk factors; however,
this does not exclude the need for correlation genotype/phe-
notype analyses as these are required to establish family
overviews and to elucidate phenotypic discrepancies and
A B
Figure 5 Comparison of thrombotic events in
patients relative to promoter PROC haplotypes.
(A) The number of thrombotic events of
patients homozygous for haplotype CGTC had a
significantly difference with the other
haplotypes when compared by Fisher’s exact
test; (B) The majority of patients homozygous
for CGTG (82%) had the nonsense mutation
c.595C>T (p.Arg199X). Hmz, homozygous; Htz,
heterozygous.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 305
Fidalgo et al. Genetic background of PC deficiency as a risk factor for VT
possibly cases of PC deﬁciency without identiﬁed mutations
(23, 37, 39). This study, although geographically limited,
illustrates the advantages of identifying the most prevalent
mutations in a region.
In conclusion, we demonstrated in this study the impor-
tance of establishing the familial thrombotic risk based on
the genetic background. Familial mutations, in association
with PROC haplotypes, correlated strongly with PC levels
as well as the thrombotic episode number and age of
onset. Therefore, familial genetic studies of 52 individuals
with low or borderline PC plasma levels allowed the iden-
tiﬁcation of suspected carriers and individuals with a
higher thrombotic risk that will permit evaluations of the
need for prophylactic measures, especially in risky situa-
tions.
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